BRPI1011005A2 - anticorpos anti-epcam - Google Patents

anticorpos anti-epcam

Info

Publication number
BRPI1011005A2
BRPI1011005A2 BRPI1011005A BRPI1011005A BRPI1011005A2 BR PI1011005 A2 BRPI1011005 A2 BR PI1011005A2 BR PI1011005 A BRPI1011005 A BR PI1011005A BR PI1011005 A BRPI1011005 A BR PI1011005A BR PI1011005 A2 BRPI1011005 A2 BR PI1011005A2
Authority
BR
Brazil
Prior art keywords
epcam antibodies
epcam
antibodies
Prior art date
Application number
BRPI1011005A
Other languages
English (en)
Portuguese (pt)
Inventor
Paus Didrik
Margareta Karlsson Jenny
Diana Cicortas Gunnarsson Lavinia
Albert Griep Remko
Michailovic Kiprianov Sergej
Original Assignee
Affitech Res As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affitech Res As filed Critical Affitech Res As
Publication of BRPI1011005A2 publication Critical patent/BRPI1011005A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
BRPI1011005A 2009-06-09 2010-06-09 anticorpos anti-epcam BRPI1011005A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18538709P 2009-06-09 2009-06-09
GBGB0909904.5A GB0909904D0 (en) 2009-06-09 2009-06-09 Product
PCT/GB2010/050969 WO2010142990A1 (en) 2009-06-09 2010-06-09 ANTI-EpCAM ANTIBODIES

Publications (1)

Publication Number Publication Date
BRPI1011005A2 true BRPI1011005A2 (pt) 2018-03-06

Family

ID=40937119

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1011005A BRPI1011005A2 (pt) 2009-06-09 2010-06-09 anticorpos anti-epcam

Country Status (8)

Country Link
US (1) US8637017B2 (https=)
EP (1) EP2440580A1 (https=)
JP (1) JP2012529281A (https=)
CN (1) CN102549017A (https=)
BR (1) BRPI1011005A2 (https=)
EA (1) EA201171463A1 (https=)
GB (1) GB0909904D0 (https=)
WO (1) WO2010142990A1 (https=)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2524124C (en) 2003-04-30 2014-03-25 Uwe Zangemeister-Wittke Methods for treating cancer using an immunotoxin
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
MY162056A (en) 2006-10-12 2017-05-31 Univ Tokyo Diagnosis and treatment of cancer using anti -ereg antibody
EP2436397B1 (en) 2009-05-29 2017-05-10 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition containing antagonist of egf family ligand as component
JP6130307B2 (ja) 2011-03-17 2017-05-17 ザ ユニバーシティ オブ バーミンガム 再指向性免疫療法
WO2012158818A2 (en) 2011-05-16 2012-11-22 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
TWI593705B (zh) * 2011-12-28 2017-08-01 Chugai Pharmaceutical Co Ltd Humanized anti-epiregulin antibody and cancer therapeutic agent containing the antibody as an active ingredient
TWI485161B (zh) * 2012-03-02 2015-05-21 中央研究院 抗上皮細胞黏著分子（ＥｐＣＡＭ）抗體及其使用方法
PL2897978T3 (pl) * 2012-09-19 2017-08-31 Abbvie Biotherapeutics Inc. Sposoby identyfikacji przeciwciał o obniżonej immunogenności
CN103387989B (zh) * 2012-09-24 2016-05-18 厦门大学 上皮细胞粘附分子的核酸适体EpCAM D及其制备方法
US20140248292A1 (en) * 2013-03-04 2014-09-04 Oslo Universitetssykehus Hf Compositions and methods for treating cancer
TW201444872A (zh) * 2013-03-06 2014-12-01 Merrimack Pharmaceuticals Inc 抗Ｃ－ＭＥＴ串聯Ｆｃ雙特異性抗體
CA2909153A1 (en) * 2013-04-12 2014-10-16 Viventia Bio Inc. Compositions and methods for detection and treatment of hepatocellular carcinoma
CN103275226B (zh) * 2013-06-09 2017-08-29 中国科学技术大学 特异性抗人上皮细胞粘附分子（EpCAM）的单克隆抗体的制备、鉴定及应用
MX2015017852A (es) * 2013-06-24 2016-08-11 Chugai Pharmaceutical Co Ltd Agente terapeutico que comprende el anticuerpo anti-epirregulina humanizado con ingrediente activo contra el carcinoma de pulmon de celulas no pequeñas excluyendo el adenocarcinoma.
WO2015048901A1 (en) 2013-10-02 2015-04-09 Viventia Bio Inc. Anti-epcam antibodies and methods of use
US10583198B2 (en) 2015-03-12 2020-03-10 Viventia Bio Inc. Dosing strategies for targeting EPCAM positive bladder cancer
EP3268040A4 (en) 2015-03-12 2018-09-12 Viventia Bio Inc. Methods of treatment for epcam positive bladder cancer
EP3770171A1 (en) * 2015-04-03 2021-01-27 XOMA Technology Ltd. Treatment of cancer using inhibitors of tgf-beta and pd-1
US11098131B2 (en) 2015-07-31 2021-08-24 Sutro Biopharma, Inc. Anti-EpCAM antibodies, compositions comprising anti-EpCAM antibodies and methods of making and using anti-EpCAM antibodies
CN109476756B (zh) 2016-03-15 2022-05-31 埃泰美德(香港)有限公司 一种多特异性Fab融合蛋白及其用途
US20190262397A1 (en) 2016-07-26 2019-08-29 Tessa Therapeutics Pte. Ltd. Chimeric antigen receptor
CN107814846A (zh) * 2016-11-14 2018-03-20 杭州华得森生物技术有限公司 针对EpCAM和Cytokeratin5的特异性抗体及其制备方法
EP3601345A1 (en) 2017-03-29 2020-02-05 H. Hoffnabb-La Roche Ag Bispecific antigen binding molecule for a costimulatory tnf receptor
SG10202102502VA (en) * 2017-09-07 2021-04-29 Dragonfly Therapeutics Inc Proteins binding nkg2d, cd16 and a tumor-associated antigen
DK3749346T3 (da) 2018-02-08 2024-09-09 Dragonfly Therapeutics Inc Antistof variable domænekombinationer rettet mod nkg2d-receptoren
EA202091887A1 (ru) 2018-02-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Комбинированная терапия рака с применением мультиспецифических связывающих белков, которые активируют естественные клетки-киллеры
WO2019164930A1 (en) 2018-02-20 2019-08-29 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use
CN108484771A (zh) * 2018-04-24 2018-09-04 南京市妇幼保健院 EpCAM单域抗体G7
JPWO2019244973A1 (ja) 2018-06-20 2021-07-08 中外製薬株式会社 標的細胞に対する免疫反応を活性化する方法およびその組成物
GB201811410D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd OX40 Binding molecules
WO2020018964A1 (en) 2018-07-20 2020-01-23 Fred Hutchinson Cancer Research Center Compositions and methods for controlled expression of antigen-specific receptors
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
US12378318B2 (en) 2018-08-08 2025-08-05 Dragonfly Therapeutics, Inc. Proteins binding NKG2D, CD16 and a tumor-associated antigen
WO2020033630A1 (en) 2018-08-08 2020-02-13 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use
EP3847196A4 (en) 2018-09-07 2023-01-04 ITabMed (HK) Limited BISPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF
TWI897855B (zh) * 2018-10-26 2025-09-21 美商免疫遺傳股份有限公司 Ｅ ｐ Ｃ Ａ Ｍ 抗體、可活化抗體及免疫偶聯物以及其用途
CA3120800A1 (en) 2018-12-17 2020-06-25 Revitope Limited Twin immune cell engager
WO2020132810A1 (en) 2018-12-24 2020-07-02 Generon (Shanghai) Corporation Ltd. Multispecific antigen binding proteins capable of binding cd19 and cd3, and use thereof
WO2020216210A1 (zh) * 2019-04-22 2020-10-29 江苏恒瑞医药股份有限公司 抗EpCAM抗体及其应用
CN110950959B (zh) * 2020-02-25 2020-07-03 和铂医药(上海)有限责任公司 靶向EpCAM的抗体及其制备和应用
CN115010811B (zh) * 2020-03-11 2024-04-19 南京融捷康生物科技有限公司 可特异性结合EpCAM的单域抗体及其应用
MX2022013944A (es) 2020-05-06 2022-11-30 Dragonfly Therapeutics Inc Proteinas que se unen al receptor activador de celulas asesinas naturales grupo 2 miembro d (nkg2d), cumulo de diferenciacion (cd16) y miembro a de la familia de dominios de lectina tipo c 12 (clec12a).
WO2021231237A2 (en) * 2020-05-11 2021-11-18 Augmenta Bioworks, Inc. Antibodies for sars-cov-2 and uses thereof
CN112359052B (zh) * 2020-08-20 2023-01-03 山东兴瑞生物科技有限公司 抗EpCAM嵌合抗原受体的编码基因、制备方法、具有该基因的质粒、免疫细胞及其应用
EP4274605A4 (en) * 2021-01-11 2025-03-12 TigaTX, Inc. INDINAVIR-BASED CHEMICALLY DIMERIZING T-CELL ENGAGING COMPOSITIONS
JP2024508894A (ja) 2021-03-03 2024-02-28 ドラゴンフライ セラピューティクス， インコーポレイテッド Ｎｋｇ２ｄ、ｃｄ１６、及び腫瘍関連抗原に結合する多特異性結合タンパク質を使用して癌を治療する方法
AR126009A1 (es) 2021-06-02 2023-08-30 Hoffmann La Roche Moléculas agonistas de unión al antígeno cd28 que se dirigen a epcam
CN113563474B (zh) * 2021-06-11 2023-05-02 广州医科大学附属第三医院（广州重症孕产妇救治中心、广州柔济医院） EpCAM-CD16-NKG2D三特异性抗体及其应用
WO2024082269A1 (zh) * 2022-10-21 2024-04-25 武汉友芝友生物制药股份有限公司 双特异性抗体在免疫细胞治疗方面的应用
PE20260306A1 (es) 2023-06-12 2026-02-11 Amgen Inc Proteinas de union a receptor de linfotoxina beta agonistas
CN119409829B (zh) * 2024-11-15 2025-08-22 康元医疗科技(大连)有限公司 抗EpCAM纳米抗体及其应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2437213A1 (fr) 1978-09-28 1980-04-25 Cm Ind Produits cytotoxiques formes par liaison covalente de la chaine a de la ricine avec un anticorps et leur procede de preparation
US4736866B1 (en) 1984-06-22 1988-04-12 Transgenic non-human mammals
WO1990010457A1 (en) 1989-03-14 1990-09-20 New York University Method of treating hiv infections using immunotoxins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
DE69232137T2 (de) 1991-11-25 2002-05-29 Enzon Inc Multivalente antigen-bindende proteine
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US5776427A (en) 1992-03-05 1998-07-07 Board Of Regents, The University Of Texas System Methods for targeting the vasculature of solid tumors
EP1306095A3 (en) 1992-03-05 2003-06-25 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
BRPI9809391B8 (pt) 1997-04-14 2021-05-25 Amgen Res Munich Gmbh processo para a produção de um receptor de antígeno anti-humano, anticorpo humano e composição farmacêutica
US8236561B2 (en) 1999-04-15 2012-08-07 Crucell Holland B.V. Efficient production of IgA in recombinant mammalian cells
GB9911569D0 (en) 1999-05-18 1999-07-21 Oxford Biomedica Ltd Antibodies
DE60038132T2 (de) 1999-12-27 2009-04-02 Crucell Holland B.V. Antikörper gegen Ep-Cam
PT1383785E (pt) * 2001-05-03 2011-06-28 Merck Patent Gmbh Anticorpo recombinante específico de tumores e utilização deste
DE10143106C1 (de) 2001-09-03 2002-10-10 Artus Ges Fuer Molekularbiolog Vermehrung von Ribonukleinsäuren
CN1812999A (zh) * 2003-05-31 2006-08-02 麦克罗梅特股份公司 包含EpCAM特异构建体的药物组合物
AU2006301492B2 (en) * 2005-10-11 2011-06-09 Amgen Research (Munich) Gmbh Compositions comprising cross-species-specific antibodies and uses thereof
EP2142570B1 (en) * 2007-04-04 2011-06-15 SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. Anti-epcam antibody and uses thereof
US8802442B2 (en) 2011-11-30 2014-08-12 Eric B. Wheeldon Apparatus and method for the remote sensing of blood in human feces and urine

Also Published As

Publication number Publication date
GB0909904D0 (en) 2009-07-22
EA201171463A1 (ru) 2012-07-30
US20100310463A1 (en) 2010-12-09
EP2440580A1 (en) 2012-04-18
US8637017B2 (en) 2014-01-28
WO2010142990A1 (en) 2010-12-16
CN102549017A (zh) 2012-07-04
JP2012529281A (ja) 2012-11-22

Similar Documents

Publication Publication Date Title
BRPI1011005A2 (pt) anticorpos anti-epcam
CY2019040I1 (el) Aνti-il-23 αντισωματα
PT2406284T (pt) Anticorpos anti-bcma
BRPI0906877A2 (pt) Anticorpos anti-trkb aperfeiçoados
BR112012030311A2 (pt) anticorpo
SI3342786T1 (sl) Anti-DLL3 protitelo
IL212175B (en) Muc1* antibodies
PT2406399T (pt) Proteínas mirac
DK2443154T3 (da) Bispecifikke antigenbindingsproteiner
HRP20171011T1 (hr) ANTI-eMET ANTITIJELO
BRPI0907237A2 (pt) Anticorpo anti-cldn6
SMT201700083B (it) Anticorpi monoclonali
EP2473531A4 (en) Anti-gitr antibodies
BRPI1014262A2 (pt) anticorpos específicos para caderina-17
EP2337798A4 (en) SPECIFIC ANTIBODIES OF THE ASB
PT2376116E (pt) Anticorpos anti-igf
DK3323830T3 (da) Anti-gd2 antibodies
BRPI0917148A2 (pt) anticorpos anti-cd5
DK3741883T3 (da) Antistofbiblioteker
EP2377932A4 (en) ANTI-Siglec-15 ANTIBODY
HUE056626T2 (hu) Antitestkészítmény
EP2482848A4 (en) Endoglin antibodies
EP2629796A4 (en) ANTIBODY
CO6791565A2 (es) Anticuerpos anti-notch1
DK3514173T3 (da) DKK-1-antistoffer

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]